Through this investigation, we found that the expression perturbation of IFC genes could lead to the resistance of several drugs which have been used for renal cell carcinoma treatment in clinical trials including targeted therapy drugs Axitinib [47,48,49,50], Sorafenib [51], Pazopanib [52,53], Sunitinib [54], and immunotherapy drugs Bevacizumab [55,56], Interleukin-2 [57,58], Pembrolizumab [47], Nivolumab [59,60]. This evidence concerns the gene IL2 and hereditary clear cell renal cell carcinoma.